Summary of findings for single‐dose nasal decongestant vs placebo
Secondary outcome: all adverse events · adult patients with the common cold
1 finding from 1 review
- no estimate extracted2 studies · 82 participantsGRADE not reported
Findings
What do systematic reviews say?
891 questions · 902 findings · 317 reviews
No studies found 210 · 23.3%GRADE not reported 56 · 6.2%Very low 236 · 26.2%Low 220 · 24.4%Moderate 146 · 16.2%High 34 · 3.8%
Summary of findings for multi‐dose nasal decongestant vs placebo
Secondary outcome: all adverse events · adult patients with the common cold
Summary of findings for multi‐dose nasal decongestant showed no clear difference in secondary outcome: all adverse events compared with placebo (low certainty).
1 finding from 1 review
- OR 0.98 [0.68, 1.4]7 studies · 1195 participantsLow
Intervention not reported
Adverse events: delayed neurotoxicity · Participants with PCNSL
1 finding from 1 review
- The role of additional radiotherapy for primary central nervous system lymphoma 2014 · Cochrane Headline outcomes onlyno estimate extracted1 study · 84 participantsVery low
Intervention not reported
Participants reporting adverse events · patients with rheumatoid arthritis pain
The intervention may leads to higher participants reporting adverse events (low certainty).
1 finding from 1 review
- OR 3.9 [2.31, 6.56]4 studies · 371 participantsLow
Fluoroquinolones vs macrolides
Serious adverse events ‐ not reported · patients with Shigella dysentery
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Cotrimoxazole vs beta‐lactams
Serious adverse events ‐ not reported · patients with Shigella dysentery
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Cotrimoxazole vs fluoroquinolones
Serious adverse events ‐ not reported · patients with Shigella dysentery
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Oral gentamicin vs nalidixic acid
Serious adverse events ‐ not reported · patients with Shigella dysentery
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Sulphonamides vs tetracycline
Serious adverse events ‐ not reported · patients with Shigella dysentery
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Antibiotics vs no drug or placebo
Serious adverse events ‐ not reported · patients with Shigella dysentery
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
TACE followed by 3‐DCRT vs chemoembolisation
Non‐serious adverse events: leukopenia · primary hepatocellular carcinoma
It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: leukopenia compared with TACE (very low certainty).
1 finding from 1 review
- Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter… 2019 · Cochrane Headline outcomes onlyRR 1.12 [0.92, 1.34]5 studies · 438 participantsVery low
Fluoroquinolones vs beta‐lactams
Other adverse events clinical criteria · patients with Shigella dysentery
It is very uncertain whether fluoroquinolones changes other adverse events clinical criteria compared with beta‐lactams (very low certainty).
1 finding from 1 review
- RR 1.03 [0.77, 1.39]4 studies · 570 participantsVery low
Fluoroquinolones vs macrolides
Other adverse events clinical criteria · patients with Shigella dysentery
It is very uncertain whether fluoroquinolones changes other adverse events clinical criteria compared with macrolides (very low certainty).
1 finding from 1 review
- RR 1.33 [0.32, 5.56]1 study · 76 participantsVery low
Cotrimoxazole vs beta‐lactams
Other adverse events clinical criteria · patients with Shigella dysentery
It is very uncertain whether cotrimoxazole changes other adverse events clinical criteria compared with beta‐lactams (very low certainty).
1 finding from 1 review
- RR 0.81 [0.27, 2.45]2 studies · 89 participantsVery low
Cotrimoxazole vs fluoroquinolones
Other adverse events clinical criteria · patients with Shigella dysentery
It is very uncertain whether cotrimoxazole changes other adverse events clinical criteria compared with fluoroquinolones (norfloxacin) (very low certainty).
1 finding from 1 review
- RR 2.82 [0.12, 66.62]1 study · 62 participantsVery low
Antibiotics vs no drug or placebo
Other adverse events clinical criteria · patients with Shigella dysentery
It is very uncertain whether antibiotic changes other adverse events clinical criteria compared with no drug or placebo (very low certainty).
1 finding from 1 review
- RR 1.43 [0.06, 34.13]1 study · 94 participantsVery low
Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP)
Infant Grade 3/4 Severe Adverse Events · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
Kesho Bora: AZT/3TC/LPV‐r showed no clear difference in infant Grade 3/4 Severe Adverse Events compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).
1 finding from 1 review
- Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes onlyRR 0.95 [0.77, 1.16]1 study · 805 participantsLow
Adjunctive Coriolus versicolor vs no adjunctive treatment
Adverse events: Neutrophils decreased ‐ · adults (aged 18+) with colorectal cancer
It is very uncertain whether adjunctive Coriolus versicolor changes adverse events: Neutrophils decreased ‐ compared with no adjunctive treatment (very low certainty).
1 finding from 1 review
- Coriolus (Trametes) versicolor mushroom to reduce adverse effects from chemotherapy or radiotherapy in people with… 2022 · Cochrane Headline outcomes onlyRR 0.41 [0.24, 0.71]3 studies · 133 participantsVery low
Intervention not reported
Severe adverse events: gastrointestinal · antiretroviral‐naïve individuals
The intervention showed no clear difference in severe adverse events: gastrointestinal (low certainty).
1 finding from 1 review
- Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse transcriptase… 2016 · Cochrane Headline outcomes onlyRR 0.76 [0.48, 1.21]6 studies · 2049 participantsLow
NB‐UVB vs UVA1
Withdrawals due to adverse events · atopic eczema
1 finding from 1 review
- no estimate extracted1 study · 13 participantsVery low